RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All News and Research Articles

Gaining clearance from the Food and Drug Administration (FDA), 2 new drug screening tests offer practitioner immediate, in-office results for the 5 most commonly abused opioid-derived drugs and for fentanyl.
Express Scripts launches an Advanced Opioid Management Program intended to limit new opioid prescriptions to no more than a week of short-acting formulations, which all but ignores pain specialists discretion and individual patient needs.
Patients with polymyalgia rheumatica are not at greater risk of developing diabetes, osteoporosis, or fractures from long-term steroid therapy than patients without PMR, according to the results of a new study.
Weight loss surgery may help overweight patients suffering from arthritis of the knee, new study finds.
Gabapentinoids are not a good substitute for opioids in the management of chronic low back pain that does not include neuropathic pain, study finds.
New form of synthetic cannabinoid, Syndros, has received FDA approval for the treatment of cachexia and nausea and vomiting in AIDS and cancer patients.
The FDA has expanded the indication for Movantik to include cancer survivors on opioid therapy for pain management who develop opioid-induced constipation.
The government is declaring war on the opioid epidemic. Practical Pain Management takes a look at what that will mean for physicians and pain patients, and how to weather this storm.
Patients with post-traumatic stress disorder who improved following prolonged exposure therapy showed similar brain activity patterns following emotional tasks, indicating an ability to predict responsiveness.
New Drug Application filed for IV meloxicam from Recro Pharma, Inc. Agent uses NanoCrystal platform to enhance bioavailability of the NSAID at lower doses.
While most patients received an opioid prescription to manage post-surgical pain, fewer than 10% of patients filled and used the full prescription.
Youth with diabetes are developing diabetic peripheral neuropathy at rates similar to that of adults, necessitating more aggressive screening and earlier management.
FDA tables NDA for new oxycodone extended-release opioid Rexista (oxycodone), citing safety concerns.
GlaxoSmithKline received approval to market a once weekly, subcutaneous injectable version of belimumab for patients with SLE, which can be self-administered.
A MultGen 2 Radiofrequency Generator gains FDA clearance to provide greater efficacy in ablation procedures to give patients greater pain relief for 1 year.
SHOW MAIN MENU
SHOW SUB MENU